Page last updated: 2024-09-02

tadalafil and warfarin

tadalafil has been researched along with warfarin in 3 studies

Compound Research Comparison

Studies
(tadalafil)
Trials
(tadalafil)
Recent Studies (post-2010)
(tadalafil)
Studies
(warfarin)
Trials
(warfarin)
Recent Studies (post-2010) (warfarin)
1,7423921,08936,5732,14314,728

Protein Interaction Comparison

ProteinTaxonomytadalafil (IC50)warfarin (IC50)
Vitamin K epoxide reductase complex subunit 1 Homo sapiens (human)0.0088

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Abadi, AH; Abdel-Halim, M; Engel, M; Fathalla, RK; Hammam, MA; Hartmann, RW; Hefnawy, A; Keeton, AB; Maher, A; Maxuitenko, Y; Piazza, GA; Racheed, NAS; Sigler, S1
Izzo, A; Khatwa, U; Kothare, SV; Kulik, T; McSweeney, J1

Reviews

2 review(s) available for tadalafil and warfarin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
"Nocturnal seizures" in idiopathic pulmonary arterial hypertension.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2013, Oct-15, Volume: 9, Issue:10

    Topics: Carbolines; Cardiac Output, Low; Child, Preschool; Diagnosis, Differential; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Oxygen Inhalation Therapy; Parasomnias; Seizures; Severity of Illness Index; Sleep Apnea Syndromes; Tadalafil; Treatment Outcome; Warfarin

2013

Other Studies

1 other study(ies) available for tadalafil and warfarin

ArticleYear
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
    Journal of medicinal chemistry, 2021, 04-22, Volume: 64, Issue:8

    Topics: Animals; Blood Proteins; Celecoxib; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Half-Life; Humans; Isoenzymes; Mice; Mice, Inbred C57BL; Microsomes, Liver; Phosphodiesterase 5 Inhibitors; Protein Binding; Pyrazoles; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship

2021